In the absence of a submission from the holder of the marketing authorisation, nilotinib (Tasigna®) cannot be endorsed for use within NHS Wales for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase; treatment of paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.